Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Viera Hrabčáková"'
Autor:
Viera Hrabčáková, Marek Borsky, Anna Panovská, Jitka Novotná, Michael Doubek, Petr Muller, Marek Mráz, Jiri Mayer, Martin Trbušek, Yvona Brychtová
Publikováno v:
Leukemia research. 111
The in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of ritu
Autor:
Jitka Malčíková, Iveta Valášková, Ludmila Bourková, Katerina Stano-Kozubik, Jana Šmardová, Marek Borsky, Hana Skuhrová Francová, Šárka Pospíšilová, Martin Trbušek, Jana Kotašková, Michael Doubek, Viera Hrabčáková, Yvona Brychtová, Jiri Mayer, Boris Tichy
Publikováno v:
Cancer Genetics and Cytogenetics. 189:53-58
B-cell chronic lymphocytic leukemia (CLL) is an incurable disease with a highly variable clinical course. A proportion of patients eventually progress to a higher stage of malignancy. A recent association has been observed between the presence of abe
Publikováno v:
Journal of Clinical Oncology. 35:e19006-e19006
e19006 Background: Chronic lymphocytic leukemia (CLL) has heterogeneous clinical course. Identification of prognostic markers is important for proper management of disease. Cytogenetics, IgVH mutation status, TP53 functional status, CD38, ZAP-70 and
Publikováno v:
Blood. 112:2081-2081
B-cell chronic lymphocytic leukemia (B-CLL) is the most common type of leukemia in the adult population. It has a heterogeneous behavior and variable prognosis. While some patients experience indolent disease requiring no therapy for many years, othe